Roche Holding AG
RHO6
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
112,774
Stocks News & Analysis
stocks
This ASX miner is the cheapest in our iron ore coverage
High debt levels and low commodity prices were a concern, but agreed sell-downs and a ramp-up of key operations should help.
stocks
Apple names new CEO as Tim Cook steps aside after 15 years
John Ternus, Apple’s hardware chief, will take up the role in September.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,090.30 | 34.90 | -0.38% |
| CAC 40 | 8,235.72 | 95.32 | -1.14% |
| DAX 40 | 24,270.87 | 146.93 | -0.60% |
| Dow JONES (US) | 49,149.38 | 293.18 | -0.59% |
| FTSE 100 | 10,498.09 | 110.99 | -1.05% |
| HKSE | 26,165.80 | 321.68 | -1.21% |
| NASDAQ | 24,259.96 | 144.43 | -0.59% |
| Nikkei 225 | 59,614.14 | 264.97 | 0.45% |
| NZX 50 Index | 12,924.65 | 7.68 | -0.06% |
| S&P 500 | 7,064.01 | 45.13 | -0.63% |
| S&P/ASX 200 | 8,864.20 | 32.60 | -0.37% |
| SSE Composite Index | 4,095.07 | 10.00 | 0.24% |